Clinical characteristics and glucose-lowering drug utilization among patients initiating liraglutide in Denmark: a routine clinical care prescription study

Jakob S. Knudsen*, Reimar W. Thomsen, Anton Pottegård, Filip K. Knop, Henrik T. Sørensen

*Corresponding author for this work

    Research output: Contribution to journalJournal articleResearchpeer-review

    145 Downloads (Pure)

    Abstract

    Highlights This population-based real-world prescription study characterized all new users of liraglutide in northern Denmark from 2009 to 2015. More than half (57%) the patients had liraglutide prescribed as part of drug combinations outside the originally approved indications. Comorbidities or diabetes complications were present in most patients, with the highest prevalence observed among the 73% of initiators who would have been ineligible for the Liraglutide Effect and Action in Diabetes (LEAD) 1-5 trials that led to liraglutide registration, underscoring the need for further post-marketing studies.

    Original languageEnglish
    JournalJournal of Diabetes
    Volume11
    Issue number8
    Pages (from-to)690-694
    ISSN1753-0393
    DOIs
    Publication statusPublished - Aug 2019

    Keywords

    • cross-sectional studies
    • diabetes pharmacology
    • drug utilization
    • glucagon-like peptide-1 receptor
    • liraglutide

    Fingerprint

    Dive into the research topics of 'Clinical characteristics and glucose-lowering drug utilization among patients initiating liraglutide in Denmark: a routine clinical care prescription study'. Together they form a unique fingerprint.

    Cite this